行情中心 沪深京A股 上证指数 板块行情 股市异动 专题 涨跌情报站 盯盘 港股 研究所 直播 股票开户 智能选股
全球指数
数据中心 资金流向 融资融券 沪深港通 比价数据 研报数据 公告掘金 新股申购 大宗交易 业绩速递

ASYMCHEM(002821):Profitability improves YoY;emerging businesses continue to ramp up

中信建投证券股份有限公司 11-06 00:00

凯莱英 --%

Key takeaway

In 9M26, the company recorded revenue growth of 16.5% YoY and a 21.8% YoY increase in Non-IFRS adjusted net profit attributable to shareholders of the parent company. In 3Q26, revenue reached RMB1.788bn, up 24.0% YoY and down 0.9% QoQ, while Non-IFRS adjusted net profit attributable to shareholders of the parent company reached RMB320mn, up 49.6% YoY. In 9M26, the company recorded solid revenue growth in its small-molecule CDMO business, while revenue from emerging businesses grew by more than 50% YoY. New orders signed in 3Q26 increased by approximately 30% YoY, with peptide and oligonucleotide orders growing rapidly. Based on the current backlog awaiting delivery, the company will enter a period of concentrated deliveries in 4Q26. Looking ahead to 2026, the current backlog is sufficient to cover the full-year target. The company maintains its full-year revenue growth guidance of 19%–22%. As orders and deliveries improve, together with higher capacity utilization and operating efficiency, profitability is expected to improve further.

Event

The company released the 9M26 earnings results

In 9M26, the company recorded operating revenue of RMB5.395bn, up 16.5% YoY and 20.0% YoY at constant exchange rates. Net profit attributable to shareholders of the parent company reached RMB852mn, up 6.5% YoY. Adjusted net profit attributable to shareholders of the parent company reached RMB1.074bn, up 21.8% YoY, with an adjusted net margin of 19.9%. Gross margin was 41.9%, up 1.12 pcts YoY at constant exchange rates. New orders signed in 3Q26 increased by approximately 30% YoY. The current backlog is sufficient to cover the full-year target, and the company maintains its guidance for 19%–22% YoY growth in operating revenue in 2026.

Risks:

Subsequent order growth and commercialization business growth may fall short of expectations: The company’s clients are innovative drug companies and multinational pharmaceutical companies, and order growth depends on clients’ innovative project initiation and product R&D progress, which involve uncertainties; Business expansion may fall short of expectations: The company is actively expanding emerging businesses and continuously investing in and building capabilities, and the expansion progress and revenue growth of new businesses involve uncertainties; Risk of loss of core technical personnel: The pharmaceutical outsourcing service industry is a technology-talent-intensive industry, and the company stabilizes its technical team by establishing various talent incentive mechanisms, with no large-scale loss of technical personnel having occurred. If large-scale loss occurs, it will have a negative impact on its normal operations. Capacity expansion and utilizat ion may fall short of expectations: The company’s peptide and biological macromolecules segments are still expanding capacity, and there may be cases where the expansion progress or capacity utilization rate falls short of expectations.

免责声明:以上内容仅供您参考和学习使用,任何投资建议均不作为您的投资依据;您需自主做出决策,自行承担风险和损失。九方智投提醒您,市场有风险,投资需谨慎。

相关股票

相关板块

  • 板块名称
  • 最新价
  • 涨跌幅

相关资讯

扫码下载

九方智投app

扫码关注

九方智投公众号

头条热搜

涨幅排行榜

  • 上证A股
  • 深证A股
  • 科创板
  • 排名
  • 股票名称
  • 最新价
  • 涨跌幅
  • 股圈